Dr. Smith Discusses CAR T Cell Persistence in Myeloma

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Smith says that a way to advance CAR T-cell therapy for patients with myeloma is with novel CAR T-cell vectors that enhance the depth and persistence of responses for patients. In myeloma, multiple studies with CD19 and BCMA CAR T cells have shown that the expansion and persistence of the gene-modified T cells correlate with deeper and more durable responses, he adds.

The reason that Smith says persistence is important is because a proportion of patients with myeloma are relapsing after CAR T-cell therapy. One reason for this relapse is that the target antigen gets downregulated or is not expressed in a small population of cells, and those cells end up growing out. For that reason, Smith says that investigators are looking at dual targeting.

Related Videos
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome Editing
Paul Harmatz, MD, on Reducing GAGs in MPS Type 2 With RGX-121 Gene Therapy
Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade Glioma
Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy
Related Content
© 2023 MJH Life Sciences

All rights reserved.